BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 23078175)

  • 1. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.
    Xiao JF; Varghese RS; Zhou B; Nezami Ranjbar MR; Zhao Y; Tsai TH; Di Poto C; Wang J; Goerlitz D; Luo Y; Cheema AK; Sarhan N; Soliman H; Tadesse MG; Ziada DH; Ressom HW
    J Proteome Res; 2012 Dec; 11(12):5914-23. PubMed ID: 23078175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis.
    Ressom HW; Xiao JF; Tuli L; Varghese RS; Zhou B; Tsai TH; Ranjbar MR; Zhao Y; Wang J; Di Poto C; Cheema AK; Tadesse MG; Goldman R; Shetty K
    Anal Chim Acta; 2012 Sep; 743():90-100. PubMed ID: 22882828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.
    Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y
    Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry.
    Wang B; Chen D; Chen Y; Hu Z; Cao M; Xie Q; Chen Y; Xu J; Zheng S; Li L
    J Proteome Res; 2012 Feb; 11(2):1217-27. PubMed ID: 22200553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of urinary pseudotargeted LC-MS-based metabolomics method and its application in hepatocellular carcinoma biomarker discovery.
    Shao Y; Zhu B; Zheng R; Zhao X; Yin P; Lu X; Jiao B; Xu G; Yao Z
    J Proteome Res; 2015 Feb; 14(2):906-16. PubMed ID: 25483141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker discovery for early detection of hepatocellular carcinoma in hepatitis C-infected patients.
    Mustafa MG; Petersen JR; Ju H; Cicalese L; Snyder N; Haidacher SJ; Denner L; Elferink C
    Mol Cell Proteomics; 2013 Dec; 12(12):3640-52. PubMed ID: 24008390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.
    Chen T; Xie G; Wang X; Fan J; Qiu Y; Zheng X; Qi X; Cao Y; Su M; Wang X; Xu LX; Yen Y; Liu P; Jia W
    Mol Cell Proteomics; 2011 Jul; 10(7):M110.004945. PubMed ID: 21518826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LC-MS profiling of N-Glycans derived from human serum samples for biomarker discovery in hepatocellular carcinoma.
    Tsai TH; Wang M; Di Poto C; Hu Y; Zhou S; Zhao Y; Varghese RS; Luo Y; Tadesse MG; Ziada DH; Desai CS; Shetty K; Mechref Y; Ressom HW
    J Proteome Res; 2014 Nov; 13(11):4859-68. PubMed ID: 25077556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolomic Characterization of Hepatocellular Carcinoma in Patients with Liver Cirrhosis for Biomarker Discovery.
    Di Poto C; Ferrarini A; Zhao Y; Varghese RS; Tu C; Zuo Y; Wang M; Nezami Ranjbar MR; Luo Y; Zhang C; Desai CS; Shetty K; Tadesse MG; Ressom HW
    Cancer Epidemiol Biomarkers Prev; 2017 May; 26(5):675-683. PubMed ID: 27913395
    [No Abstract]   [Full Text] [Related]  

  • 10. GC-MS Based Plasma Metabolomics for Identification of Candidate Biomarkers for Hepatocellular Carcinoma in Egyptian Cohort.
    Nezami Ranjbar MR; Luo Y; Di Poto C; Varghese RS; Ferrarini A; Zhang C; Sarhan NI; Soliman H; Tadesse MG; Ziada DH; Roy R; Ressom HW
    PLoS One; 2015; 10(6):e0127299. PubMed ID: 26030804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of novel biomarkers of hepatocellular carcinoma by high-definition mass spectrometry: Ultrahigh-performance liquid chromatography quadrupole time-of-flight mass spectrometry and desorption electrospray ionization mass spectrometry imaging.
    Nagai K; Uranbileg B; Chen Z; Fujioka A; Yamazaki T; Matsumoto Y; Tsukamoto H; Ikeda H; Yatomi Y; Chiba H; Hui SP; Nakazawa T; Saito R; Koshiba S; Aoki J; Saigusa D; Tomioka Y
    Rapid Commun Mass Spectrom; 2020 Apr; 34 Suppl 1(Suppl 1):e8551. PubMed ID: 31412144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LC-MS/MS isomeric profiling of permethylated N-glycans derived from serum haptoglobin of hepatocellular carcinoma (HCC) and cirrhotic patients.
    Huang Y; Zhou S; Zhu J; Lubman DM; Mechref Y
    Electrophoresis; 2017 Sep; 38(17):2160-2167. PubMed ID: 28543513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LC-MS/MS-based serum proteomics for identification of candidate biomarkers for hepatocellular carcinoma.
    Tsai TH; Song E; Zhu R; Di Poto C; Wang M; Luo Y; Varghese RS; Tadesse MG; Ziada DH; Desai CS; Shetty K; Mechref Y; Ressom HW
    Proteomics; 2015 Jul; 15(13):2369-81. PubMed ID: 25778709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic Characterization Analysis of Human Hepatocarcinoma by Urine Metabolomics Approach.
    Liang Q; Liu H; Wang C; Li B
    Sci Rep; 2016 Jan; 6():19763. PubMed ID: 26805550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography-mass spectrometry.
    Cao H; Huang H; Xu W; Chen D; Yu J; Li J; Li L
    Anal Chim Acta; 2011 Apr; 691(1-2):68-75. PubMed ID: 21458633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepatocellular carcinoma diagnosis.
    Tan Y; Yin P; Tang L; Xing W; Huang Q; Cao D; Zhao X; Wang W; Lu X; Xu Z; Wang H; Xu G
    Mol Cell Proteomics; 2012 Feb; 11(2):M111.010694. PubMed ID: 22084000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.
    Fitian AI; Nelson DR; Liu C; Xu Y; Ararat M; Cabrera R
    Liver Int; 2014 Oct; 34(9):1428-44. PubMed ID: 24661807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early hepatocellular carcinoma in patients with cirrhosis.
    Guo Y; Zhao J; Bi J; Wu Q; Wang X; Lai Q
    J Hematol Oncol; 2012 Jul; 5():37. PubMed ID: 22760167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples.
    Göbel T; Vorderwülbecke S; Hauck K; Fey H; Häussinger D; Erhardt A
    World J Gastroenterol; 2006 Dec; 12(47):7604-12. PubMed ID: 17171788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of hepatocellular carcinoma in hepatitis C patients: biomarker discovery by LC-MS.
    Bowers J; Hughes E; Skill N; Maluccio M; Raftery D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Sep; 966():154-62. PubMed ID: 24666728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.